



Press Release

CILIAN develops an innovative Influenza subunit vaccine together with European collaborative research programme ADITEC.

Münster, March 30, 2014:

CILIAN AG is now an affiliated member of the **European collaborative research programme Advanced Immunization Technologies (ADITEC)**. Within this consortium CILIAN intends to improve efficacy of its own seasonal influenza subunit vaccine **CiFlu®** (brand name in Europe) using novel and powerful immunization technologies. CILIAN's vaccine already features significant improvements in production speed and cost of goods as compared to currently available products which may be further improved substantially in this collaboration.

In this multidisciplinary consortium CILIAN will collaborate in the area of vaccine formulation with three leading scientific research groups of European universities and research centres.

CILIAN will co-develop a nano-particle based seasonal Influenza subunit vaccine with Dr. Bernard Verrier of the French research centre CNRS (*Centre national de la recherche scientifique*) and nanotechnology company ADJUVATIS SAS, to further improve efficacy of CILIAN's vaccine.

With the University of Siena (Italy) and the national research institute CEA (France) CILIAN will perform additional preclinical studies for the influenza vaccine.

About ADITEC

ADITEC is a multinational collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries and 42 research partners collaborate in the ADITEC project.

ADITEC comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. Different aspects of vaccination, from basic research, new technologies to clinical trials and public health, are covered. Details can be found on the project website www.aditecproject.eu.

About CILIAN AG

CILIAN AG is a German based biotechnology company that is engaged in the development and application of recombinant products through its proprietary innovative expression system using eukaryotic, single cell microorganisms, called ciliates, as its production organisms. Ciliates are currently employed in the development and production of a pipeline of subunit vaccines, therapeutic enzymes and monoclonal antibodies.

Contact:

Dr. Marcus Hartmann, PhD
CSO
Cilian AG
Johann-Krane Weg 42
D-48149 Münster
Germany
www.cilian.com
+49 251 620 31 0
hartmann@cilian.de